DMT 210

Drug Profile

DMT 210

Alternative Names: DMT210; SIG 990

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Signum Biosciences
  • Developer Dermata Therapeutics; Signum Biosciences
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules; Terpenes
  • Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Rosacea
  • Research Acne vulgaris

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Rosacea (In adults) in USA (Topical) (NCT03003104)
  • 01 Oct 2016 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT02949960)
  • 28 Sep 2016 Early Research development is ongoing in Atopic dermatitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top